Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2026 07:00 ET | Source: Exousia Pro, Inc.

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

OTCID:MAJI announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company
June 09, 2026 07:00 ET | Source: Exousia Pro, Inc.

NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University

MAJI announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board.
June 02, 2026 11:23 ET | Source: Exousia Pro, Inc.

NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization

NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
May 11, 2026 11:53 ET | Source: Exousia Pro, Inc.

NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist

(OTCPK: MAJI) announce the commencement of the final stability phase for its inaugural line of commercial exosome products.
April 07, 2026 10:30 ET | Source: Exousia Pro, Inc.

NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test

Exousia Pro, OTCPK: MAJI, announces the commencement of the first critical phase in bringing its revolutionary cancer screening test to the global market.
March 16, 2026 10:15 ET | Source: Exousia Pro, Inc.

Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value

OTC.MAJI Announces landmark agreement represents a pivotal financial milestone for the Company, delivering immediate and substantial value.
March 05, 2026 13:00 ET | Source: Exousia Pro, Inc.

Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions

(OTCPK: MAJI) announces several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint.
February 10, 2026 10:30 ET | Source: Exousia Pro, Inc.

Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition

Exousia Pro, Inc. (OTCID: MAJI to acquire an established telehealth organization.